Wall Street analyst estimates for Forte Biosciences, Inc. (FBRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.90 | ||
| 2026-08-11 | $-0.97 | $-1.08 | +10.2% |
| 2026-05-21 | $-1.24 | $-1.16 | -6.9% |
| 2026-03-31 | $-1.45 | $-1.42 | -2.1% |
| 2025-11-14 | $-0.99 | $-1.04 | +4.8% |
| 2025-08-14 | $-0.96 | $-1.21 | +20.7% |
| 2025-05-15 | $-1.37 | $-0.89 | -53.9% |
| 2025-03-24 | $-2.45 | $-4.55 | +46.2% |
Valuation Ratios
| Price / Book | 9.96 |
| EV / EBITDA | -17.71 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49000 | $41000 | $18.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $11000 | $54000 | $36000 | 0 | $9000 | $39000 | $64000 |
| Gross Profit | $49000 | $41000 | $18.0M | -$11000 | -$54000 | -$36000 | 0 | -$9000 | -$39000 | -$64000 |
| Research & Development | $27.2M | $29.1M | $50.5M | $2.7M | $9.9M | $13.9M | $5.6M | $21.9M | $21.2M | $58.2M |
| Selling, General & Admin | $4.3M | $8.3M | $12.8M | $1.4M | $4.2M | $7.6M | $8.3M | $10.6M | $15.4M | $12.4M |
| Operating Expenses | $31.5M | $37.4M | $63.3M | $4.1M | $14.2M | $21.5M | $13.9M | $32.5M | $36.6M | $70.7M |
| Operating Income | -$31.7M | -$37.6M | -$45.9M | -$4.1M | -$14.2M | -$21.5M | -$13.9M | -$32.5M | -$36.6M | -$70.7M |
| EBITDA | -$31.2M | -$36.7M | -$43.7M | -$4.1M | -$46.4M | -$21.7M | -$13.8M | -$31.5M | -$35.4M | -$68.3M |
| Interest Expense | -$1.8M | $1.9M | $173380 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$33.5M | -$38.9M | -$47.3M | -$4.1M | -$46.5M | -$21.7M | -$13.9M | -$31.5M | -$35.5M | -$68.3M |
| Income Tax | 0 | 0 | $1.7M | 0 | 0 | 0 | 0 | 0 | 0 | $1.0M |
| Net Income | -$33.5M | -$38.9M | -$49.0M | -$4.1M | -$46.5M | -$21.7M | -$13.9M | -$31.5M | -$35.5M | -$69.4M |
| EPS | $-634.80 | $-997.50 | $-915.18 | $-48.25 | $-157.93 | $-38.85 | $-19.96 | $-24.92 | $-12.17 | $-4.71 |
| EPS (Diluted) | $-634.80 | $-997.50 | $-915.18 | $-48.25 | $-157.93 | $-38.85 | $-19.96 | $-24.92 | $-12.17 | $-4.71 |
| Shares Outstanding (Diluted) | $52738 | $38953 | $53492 | $84330 | $294357 | $558712 | $695341 | $1.3M | $2.9M | $14.7M |
Price
| Price | $76.99 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACTU · ALEC · APLT · CRBP · CRDF · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of FBRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks